Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary
Yang‐Min Ning(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Haw-Jyh Chiu(United States Food and Drug Administration), Nitin Mehrotra(Center for Drug Evaluation and Research), Robert Justice(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Dhananjay Marathe(United States Food and Drug Administration), Christy L. Cottrell(United States Food and Drug Administration), Jeanne Fourie Zirkelbach(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Stella Karuri(United States Food and Drug Administration), Qi Liu(Hebei Medical University), Debasis Ghosh(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), John K. Leighton, William F. Pierce(United States Food and Drug Administration), V. Ellen Maher(United States Food and Drug Administration)
Cited by 67
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k